PRESS KIT

Summary

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.

Technology Overview

AbCellera’s full-stack, AI-powered drug discovery platform, which integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science, empowers drug developers of all sizes to move quickly, reduce costs, and tackle the toughest problems in drug development.

Quotes

“We believe that AbCellera’s technology will assist us in rapidly identifying the best antibodies against a large number of agonist targets, as well as other historically difficult targets, for both oncology and immunology applications.”
Fred Schwarzer, CEO of IGM Biosciences
“AbCellera’s operating system for antibody discovery addresses each step in the process to dramatically improve the cycle time, cost, and probability of success, and we look forward to working together to advance unique clinical candidates against key disease targets.”
Carlos Garcia-Echeverria, PhD, EQRx Chief of Rx Creation
“This collaboration will allow us to gain access to AbCellera’s cutting edge, AI-powered antibody discovery platform, which will greatly accelerate and increase the efficiency of our internal discovery efforts.”
Jennifer Yang, PhD, Chief Scientific Officer of Everest Medicines
"We continue to be impressed with the speed of discovery, the quality, and the diversity of the antibodies AbCellera delivers. Through this agreement, we have secured expanded access to an industry-leading technology to accelerate the discovery of antibody-based therapies for patients with neurological diseases."
Alexander Schuth, COO